BICO Group Appoints New CFO

/

BICO Group AB today announces the appointment of Jacob Thordenberg as Group CFO. Thordenberg will begin his employment in his new position as Group CFO today, on January 2, 2023, and will be part of the company’s executive management team.

Jacob Thordenberg has a Master of Science in Corporate and Financial Management, and has more than ten years’ experience from mergers and acquisitions from Deloitte, Telia and BICO Group AB. Most recently he comes from a role as Head of M&A at BICO, where he has been since December 2021. “We are incredibly pleased to welcome Jacob to the executive team at BICO,” says Erik Gatenholm President & CEO. “His previous experience managing key initiatives to strengthen profitability and cash flow at BICO along with all merger and acquisition projects, will be an important asset for us on our ambitious journey ahead. Jacob is very familiar with all the companies in the Group and has integrated many of them throughout 2022, which has led to significant improvements.” Thordenberg succeeds Mikael Engblom, who has been interim Group CFO since May 2022. Engblom will continue to advise the company on strategic projects. “I would like to sincerely thank Mikael Engblom for his valuable contributions in developing BICO and I wish him all the best for the future,” adds Gatenholm. “We are happy that he will be with us during the transition period and beyond as an advisor.” Erik Gatenholm President & CEO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

< | >